Certified by Founder
Lodge
Ability Biologics
start up
Canada
- Montreal, Quebec
- 07/12/2023
- Seed
- $12,000,000
Our Mission:
Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
The premier biotherapeutic targeting company
Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics.
We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.
- Industry Biotechnology Research
- Website https://ability.bio/
- LinkedIn https://www.linkedin.com/company/ability-biologics/about/
Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)